Heat Biologics: Doubles after positive cancer trial of cell therapy

Scorpius Holdings

09/02/2021 14:15

** Drug developer's  HTBX.O  shares soar 107% to $17.33
premarket, set to open at a 6-month high 
    ** HTBX says a mid-stage trial of its cell therapy with
Bristol-Myers Squibb's  BMY.N  Opdivo showed the combination
therapy helped extend survival in lung cancer patients,
according to interim data (https://bit.ly/3pb0vag)
    ** The combination showed a survival rate of 61.7% over one
year in a group of patients with advanced lung cancer 
    ** Co's drug, HS-110, is a cell-based therapy designed to
activate patients' immune system against tumors 
    ** Up to Monday's close, stock had risen over four-fold in
the past 12 months 

 (Reporting by Manas Mishra in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manasmishra24))